D59.2 Drug-induced nonautoimmune hemolytic anemia

Name of the Condition

• Drug-induced nonautoimmune hemolytic anemia (ICD-10 Code: D59.2)

Summary

Drug-induced nonautoimmune hemolytic anemia is a condition where medications directly damage red blood cells, leading to their premature destruction and resulting in anemia. Unlike autoimmune forms, this condition does not involve the immune system attacking the cells. The destruction occurs due to the toxic or oxidative effects of the drug on red blood cells, reducing their lifespan and impairing oxygen transport.

Causes

The primary cause is the direct toxic effect of specific medications on red blood cells. These drugs can disrupt cell membranes or alter cellular metabolism, leading to hemolysis. Common culprits include certain antibiotics, antimalarials, and chemotherapeutic agents, though the exact mechanism varies by drug.

Risk Factors

• Use of medications known to cause direct red blood cell damage (e.g., dapsone, nitrofurantoin, or high-dose vitamin C)
• Prolonged or high-dose exposure to these drugs
• Underlying conditions that may increase susceptibility to drug toxicity (e.g., glucose-6-phosphate dehydrogenase deficiency)

Symptoms

• Fatigue and weakness
• Pale or yellowish skin (jaundice)
• Dark urine
• Shortness of breath
• Rapid heart rate
• Enlarged spleen (splenomegaly)
• Dizziness or lightheadedness

Diagnosis

Diagnosis involves blood tests to assess red blood cell destruction and anemia, including a complete blood count (CBC), reticulocyte count, bilirubin levels, and lactate dehydrogenase (LDH) tests. Additional tests may evaluate for drug exposure and rule out other causes of hemolysis.

Treatment Options

• Discontinuation of the offending drug
• Supportive care, such as blood transfusions if severe anemia is present
• Monitoring for resolution of symptoms and lab abnormalities

Prognosis and Follow-Up

Prognosis is generally favorable with prompt discontinuation of the drug. Most patients recover fully, though recovery time depends on the extent of red blood cell damage. Follow-up may include repeat blood tests to confirm resolution and monitor for recurrence if re-exposure occurs.

Complications

• Severe anemia requiring transfusion
• Acute kidney injury (rare, due to hemoglobin release)
• Prolonged recovery if drug exposure is not identified or discontinued promptly

Lifestyle & Prevention

• Avoid known offending medications when possible
• Inform healthcare providers of any history of drug-induced hemolysis
• Discuss alternative treatments with a provider if a high-risk drug is prescribed

When to Seek Professional Help

Seek immediate medical attention if symptoms of severe anemia develop, such as chest pain, severe shortness of breath, or fainting, or if dark urine or jaundice is noticed after starting a new medication.

Tips for Medical Coders

Document the specific drug or class of drugs associated with the hemolysis, as this supports the nonautoimmune etiology. Include details on drug exposure timing, discontinuation, and any resulting complications to ensure accurate coding and clinical correlation.